Short answer
REGENXBIO Inc. (RGNX) filed its Q1 2026 10-Q quarterly report on May 14, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $6M (down 92.8% year over year) with net income of −$90M.
Q1 2026 key financials · XBRL
- Revenue
- $6M
- −92.8% YoY
- Net income
- −$90M
- −1580.4% YoY
- Operating margin
- -1304.0%
- EPS (diluted)
- −$1.72
- −1533.3% YoY
Source: XBRL data from the REGENXBIO Inc. (RGNX) Q1 2026 10-Q on SEC EDGAR. USD.
REGENXBIO Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No disclosed changes from the most recent 10-K
- March 18, 2026 settlement agreement with GlaxoSmithKline filed as a new exhibit
- No Rule 10b5-1 trading-plan activity during the quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other REGENXBIO Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.